Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Astellas Pharma Income from Continuous Operations 2012-2024 | ALPMY

Astellas Pharma annual/quarterly income from continuous operations history and growth rate from 2012 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
  • Astellas Pharma income from continuous operations for the quarter ending June 30, 2024 was $0.241B, a 13.82% decline year-over-year.
  • Astellas Pharma income from continuous operations for the twelve months ending June 30, 2024 was $0.674B, a 62.21% decline year-over-year.
  • Astellas Pharma annual income from continuous operations for 2024 was $0.113B, a 84.77% decline from 2023.
  • Astellas Pharma annual income from continuous operations for 2023 was $0.742B, a 27.04% decline from 2022.
  • Astellas Pharma annual income from continuous operations for 2022 was $1.017B, a 6.35% decline from 2021.
  
Astellas Pharma Annual Income from Continuous Operations
(Millions of US $)
2024 $113
2023 $742
2022 $1,017
2021 $1,086
2020 $1,793
2019 $2,002
2018 $1,554
2017 $1,953
2016 $1,608
2015 $1,236
2014 $882
2013 $881
2012 $981
2011 $836
2010 $1,319
2009 $1,761
Astellas Pharma Quarterly Income from Continuous Operations
(Millions of US $)
2024-06-30 $241
2023-12-31
2023-06-30 $242
2022-06-30 $191
2021-06-30 $279
2020-06-30 $469
2019-06-30 $533
2018-06-30 $502
2017-06-30 $382
2016-09-30 $475
2016-06-30 $619
2016-03-31 $258
2015-12-31 $505
2015-09-30 $479
2015-06-30 $366
2015-03-31 $164
2014-12-31 $393
2014-09-30 $327
2014-06-30 $351
2014-03-31
2013-12-31
2013-09-30
2013-06-30 $223
2013-03-31
2012-12-31
2012-09-30
2012-06-30 $444
2012-03-31
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $18.223B $11.108B
Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment of atopic dermatitis in the topical immunomodulator class, Harnal to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder and Fungard an antifungal agent. Astellas Pharma, Inc. is headquartered in Tokyo, Japan.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $79.207B 30.48
Takeda Pharmaceutical (TAK) Japan $43.337B 9.02
Sandoz Group AG (SDZNY) Switzerland $19.481B 0.00
Merck (MKKGY) Germany $19.205B 17.20
United Therapeutics (UTHR) United States $16.104B 15.84
Summit Therapeutics (SMMT) United States $14.749B 0.00
Neurocrine Biosciences (NBIX) United States $12.062B 31.94
Shionogi (SGIOY) Japan $11.921B 11.42
Catalent (CTLT) United States $10.687B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.062B 6.91
Madrigal Pharmaceuticals (MDGL) United States $6.852B 0.00
Orion OYJ (ORINY) Finland $6.653B 18.71
Corcept Therapeutics (CORT) United States $5.690B 43.10
Ionis Pharmaceuticals (IONS) United States $5.329B 0.00
Crinetics Pharmaceuticals (CRNX) United States $5.116B 0.00
PTC Therapeutics (PTCT) United States $3.036B 0.00
Dyne Therapeutics (DYN) United States $3.020B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.613B 15.63
Catalyst Pharmaceuticals (CPRX) United States $2.551B 11.56
Arrowhead Pharmaceuticals (ARWR) United States $2.312B 0.00
Soleno Therapeutics (SLNO) United States $2.233B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $2.188B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.907B 0.00
Evotec AG (EVO) Germany $1.825B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.797B 0.00
Xencor (XNCR) United States $1.654B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.493B 0.00
Indivior (INDV) United States $1.442B 5.87
Harrow (HROW) United States $1.414B 0.00
Ocular Therapeutix (OCUL) United States $1.402B 0.00
Cassava Sciences (SAVA) United States $1.347B 0.00
ARS Pharmaceuticals (SPRY) United States $1.340B 0.00
Guardian Pharmacy Services (GRDN) United States $1.339B 0.00
Enliven Therapeutics (ELVN) United States $1.279B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.164B 0.00
Ardelyx (ARDX) United States $1.135B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $1.032B 0.00
Collegium Pharmaceutical (COLL) United States $0.959B 5.24
Bioventus (BVS) United States $0.941B 29.72
Relay Therapeutics (RLAY) United States $0.803B 0.00
Cronos Group (CRON) Canada $0.776B 0.00
USANA Health Sciences (USNA) United States $0.744B 13.80
Elite Pharmaceuticals (ELTP) United States $0.721B 0.00
Exscientia (EXAI) United Kingdom $0.633B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.610B 0.00
Tourmaline Bio (TRML) United States $0.603B 0.00
Organogenesis (ORGO) United States $0.541B 0.00
Altimmune (ALT) United States $0.531B 0.00
ProKidney (PROK) United States $0.521B 0.00
Savara (SVRA) United States $0.505B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.488B 0.00
Zevra Therapeutics (ZVRA) United States $0.479B 0.00
Esperion Therapeutics (ESPR) United States $0.475B 0.00
OmniAb (OABI) United States $0.454B 0.00
Xeris Biopharma Holdings (XERS) United States $0.449B 0.00
Siga Technologies (SIGA) United States $0.447B 5.22
Aquestive Therapeutics (AQST) United States $0.439B 0.00
Korro Bio (KRRO) United States $0.437B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.421B 170.79
Verve Therapeutics (VERV) United States $0.410B 0.00
Larimar Therapeutics (LRMR) United States $0.407B 0.00
4D Molecular Therapeutics (FDMT) United States $0.401B 0.00
Akebia Therapeutics (AKBA) United States $0.397B 0.00
KalVista Pharmaceuticals (KALV) United States $0.391B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.358B 0.00
Avita Medical (RCEL) United States $0.340B 0.00
Aclaris Therapeutics (ACRS) United States $0.328B 0.00
Lyell Immunopharma (LYEL) United States $0.310B 0.00
Sage Therapeutics (SAGE) United States $0.300B 0.00
Nature's Sunshine Products (NATR) United States $0.295B 17.55
Aldeyra Therapeutics (ALDX) United States $0.294B 0.00
Pyxis Oncology (PYXS) United States $0.247B 0.00
Silence Therapeutics (SLN) United Kingdom $0.209B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.202B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.200B 0.00
Lexeo Therapeutics (LXEO) United States $0.199B 0.00
Acrivon Therapeutics (ACRV) United States $0.199B 0.00
Profound Medical (PROF) Canada $0.193B 0.00
Nektar Therapeutics (NKTR) United States $0.190B 0.00
Heron Therapeutics (HRTX) United States $0.181B 0.00
Nanobiotix S.A (NBTX) France $0.178B 0.00
Galectin Therapeutics (GALT) United States $0.173B 0.00
MediWound (MDWD) Israel $0.170B 0.00
Achieve Life Sciences (ACHV) Canada $0.149B 0.00
CytoDyn (CYDY) United States $0.146B 0.00
Incannex Healthcare (IXHL) Australia $0.136B 0.00
Cardiol Therapeutics (CRDL) Canada $0.135B 0.00
Telomir Pharmaceuticals (TELO) United States $0.131B 0.00
Context Therapeutics (CNTX) United States $0.124B 0.00
Avalo Therapeutics (AVTX) United States $0.115B 0.00
Journey Medical (DERM) United States $0.111B 0.00
VAXART, INC (VXRT) United States $0.110B 0.00
Century Therapeutics (IPSC) United States $0.109B 0.00
Fractyl Health (GUTS) United States $0.105B 0.00
Innate Pharma SA (IPHYF) France $0.103B 0.00
Karyopharm Therapeutics (KPTI) United States $0.097B 0.00
Assertio Holdings (ASRT) United States $0.093B 24.37
Regulus Therapeutics (RGLS) United States $0.093B 0.00
Arch Biopartners (ACHFF) Canada $0.093B 0.00
Relmada Therapeutics (RLMD) United States $0.090B 0.00
CASI Pharmaceuticals (CASI) China $0.083B 0.00
PMV Pharmaceuticals (PMVP) United States $0.082B 0.00
ESSA Pharma (EPIX) Canada $0.077B 0.00
Vivani Medical (VANI) United States $0.076B 0.00
Swiftmerge Acquisition (IVCP) United States $0.076B 0.00
Inotiv (NOTV) United States $0.073B 0.00
Scienture Holdings (SCNX) United States $0.069B 0.00
ElectroCore (ECOR) United States $0.066B 0.00
AlloVir (ALVR) United States $0.065B 0.00
Metagenomi (MGX) United States $0.063B 0.00
Champions Oncology (CSBR) United States $0.062B 0.00
Mural Oncology (MURA) Ireland $0.057B 0.00
Nutriband (NTRB) United States $0.055B 0.00
Prelude Therapeutics (PRLD) United States $0.053B 0.00
OptiNose (OPTN) United States $0.051B 0.00
Unicycive Therapeutics (UNCY) United States $0.050B 0.00
Protara Therapeutics (TARA) United States $0.048B 0.00
Rafael Holdings (RFL) United States $0.047B 0.00
Gain Therapeutics (GANX) United States $0.046B 0.00
SCYNEXIS (SCYX) United States $0.045B 0.00
BioLineRx (BLRX) Israel $0.043B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.042B 0.00
Iterum Therapeutics (ITRM) Ireland $0.042B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.041B 0.00
VYNE Therapeutics (VYNE) United States $0.040B 0.00
CERo Therapeutics Holdings (CERO) United States $0.039B 0.00
Carisma Therapeutics (CARM) United States $0.036B 0.00
FibroGen (FGEN) United States $0.035B 0.00
Citius Pharmaceuticals (CTXR) United States $0.035B 0.00
Surrozen (SRZN) United States $0.033B 0.00
BioVie (BIVI) United States $0.033B 0.00
DURECT (DRRX) United States $0.030B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.028B 0.00
Oruka Therapeutics (ORKA) United States $0.027B 0.00
Natural Alternatives (NAII) United States $0.026B 0.00
Lipocine (LPCN) United States $0.025B 0.00
GlycoMimetics (GLYC) United States $0.024B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.022B 0.00
Enlivex Therapeutics (ENLV) Israel $0.022B 0.00
Tempest Therapeutics (TPST) United States $0.022B 0.00
MEI Pharma (MEIP) United States $0.019B 0.00
ProPhase Labs (PRPH) United States $0.018B 0.00
Cosmos Health (COSM) United States $0.017B 0.00
PolyPid (PYPD) Israel $0.017B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.017B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.016B 0.00
Mannatech (MTEX) United States $0.015B 0.00
TherapeuticsMD (TXMD) United States $0.015B 0.00
Inhibikase Therapeutics (IKT) United States $0.015B 0.00
NRx Pharmaceuticals (NRXP) United States $0.015B 0.00
Minerva Neurosciences (NERV) United States $0.015B 0.00
Nuvilex (PMCB) United States $0.014B 0.00
Vivos Therapeutics (VVOS) United States $0.014B 0.00
Lyra Therapeutics (LYRA) United States $0.013B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.012B 0.00
Talphera (TLPH) United States $0.011B 0.00
Indaptus Therapeutics (INDP) United States $0.011B 0.00
Dominari Holdings (DOMH) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.010B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.010B 0.00
Jaguar Animal Health (JAGX) United States $0.009B 0.00
Conduit Pharmaceuticals (CDT) United States $0.009B 0.00
Redhill Biopharma (RDHL) Israel $0.009B 0.00
Traws Pharma (TRAW) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.008B 0.00
Plus Therapeutics (PSTV) United States $0.007B 0.00
Viracta Therapeutics (VIRX) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Klotho Neurosciences (KLTO) United States $0.006B 0.00
Ainos (AIMD) United States $0.006B 0.00
Mangoceuticals (MGRX) United States $0.006B 0.00
TransCode Therapeutics (RNAZ) United States $0.006B 0.00
Biomerica (BMRA) United States $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.004B 0.00
SHINECO (SISI) China $0.004B 0.00
Aptorum Group (APM) United Kingdom $0.004B 0.00
Avenue Therapeutics (ATXI) United States $0.004B 0.11
Alaunos Therapeutics (TCRT) United States $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
Oncternal Therapeutics (ONCT) United States $0.003B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.003B 0.00
TNF Pharmaceuticals (TNFA) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Phio Pharmaceuticals (PHIO) United States $0.003B 0.00
Molecular Templates (MTEM) United States $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
Petros Pharmaceuticals (PTPI) United States $0.003B 0.00
SciSparc (SPRC) Israel $0.002B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
Bio-Path Holdings (BPTH) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
China SXT Pharmaceuticals (SXTC) China $0.002B 0.00
Aditxt (ADTX) United States $0.001B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.001B 0.00
Qualigen Therapeutics (QLGN) United States $0.001B 0.00
PainReform (PRFX) Israel $0.001B 0.00
Universe Pharmaceuticals INC (UPC) China $0.001B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 1.02
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 35.59